A long-term, prospective, observational cohort study of the safety and effectiveness of etanercept for the treatment of patients with paediatric psoriasis in a naturalistic setting
Volume 33, issue 1, January-February 2023
[4]Pinson R, Sotoodian B, Fiorillo L. Psoriasis in children. Psoriasis (Auckl). 2016;6:121-9.
[5]Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31:205-12.
[6]Megna M, Napolitano N, Balato A. Psoriasis in children: A review. Curr Pediatr Rev. 2015;11:10-26.
[7]Menter A, Strober BE, Kaplan DH. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-72.
[8]Menter A, Cordoro KM, Davis DMR. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82:161-201.
[9]Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther. 2011;33:679-707.
[10]Wilkinson N, Jackson G, Gardner-Medwin J. Biologic therapies for juvenile arthritis. Arch Dis Child. 2003;88:186-91.
[11]Lovell DJ, Reiff A, Jones OY. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2006;54:1987-94.
[12]Lovell DJ, Reiff A, Ilowite NT. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58:1496-504.
[18]Menter A, Korman NJ, Elmets CA. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65:137-74.
[19]Paller AS, Siegfried EC, Pariser DM. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 2016;74:280-7. e1-3.
[20]Di Lernia V, Guarneri C, Stingeni L. Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study. J Dermatolog Treat. 2018;29:217-9.
[21]Paller AS, Siegfried EC, Langley RG. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358:241-51.
[22]Constantin T, Foeldvari I, Vojinovic J. Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitis-related arthritis, or psoriatic arthritis. J Rheumatol. 2016;43:816-24.
[23]Thaçi D, Papp K, Marcoux D. Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study. Br J Dermatol. 2019;181:1177-89.
[24]Philipp S, Menter A, Nikkels AF. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (>/= 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study. Br J Dermatol. 2020;183:664-72.
[25]Bodemer C, Kaszuba A, Kingo K. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol. 2021;35:938-47.
[26]Paller AS, Seyger MMB, Alejandro Magariños G. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol. 2020;183:231-41.
[27]Bronckers I, Seyger MMB, West DP. Safety of systemic agents for the treatment of pediatric psoriasis. JAMA Dermatol. 2017;153:1147-57.
[28]Leonardi C, Strober B, Gottlieb AB. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol. 2010;9:928-37.